



H.C. Wainwright 24th Annual Global Investment Conference

Karim Mikhail
President & CEO



September 12, 2022

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, patent litigation, generic product launch, intellectual property, cash flow, research and development, and other statements that are forward-looking in nature and depend upon or refer to future events or conditions, including financial guidance and milestones.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the “Risk Factors” section in Amarin’s most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.



Karim Mikhail
President & CEO

AMARIN

BUSINESS UPDATE

Amarin Growth Strategy

Height - Portfolio Diversification

- 1 Differentiate and grow with IPE Life Cycle
- 2 Diversify through Business Development


Depth - Operational Evolution

- ★ Go-to-Market Model Transformation

Breadth - Geographic Expansion

- 1 Stabilize the US
- 2 Launch in Europe
- 3 Expand Internationally

Total Revenue by Quarter



Second Quarter 2022 Results

- Second quarter 2022 total net revenue was **\$94.4 MILLION**, including U.S. product revenue of **\$90.6 MILLION**.
- U.S. net revenues continued to be impacted by a third generic entrant to the market, resulting in lower volume and lower average net selling price.
- Importantly, the second quarter was the first full quarter where three generic entrants were in the market versus one generic entrant in the prior year period.
- Amarin saw a normalization of the trade destocking experienced in the first quarter of 2022. Exclusive business has stabilized.
- Amarin is offsetting market dynamics with cost containment efforts; announced cost reduction plan in June to reduce operating costs by approximately **\$100 MILLION OVER THE NEXT 12 MONTHS**.
- Amarin continues to actively monitor key performance indicators in the U.S. market to support our steps forward.

Progress: Third Quarter to Date

US Business Demonstrating Encouraging Trends

- Recent stable prescription trends based on previous 10-plus weeks of trends*
- Exclusive business remains relatively stable

Cash Preservation Initiatives On Track

- Cost savings plans to achieve \$100 million in annual savings by mid- 2023 on target
- Renegotiations of supply agreements continue to progress resulting in reduction of inventory purchases
- Prudent timing of investments in Europe based on reimbursement progress

European Reimbursement Discussions Underway

- Additional decisions and progress in major markets possible prior to year-end 2022

International Expansion Plans On Track

- Regulatory approvals in up to six markets by year-end with partnership activities underway

Ongoing Development of Scientific Evidence to Support VASCEPA/VAZKEPA

- Strong presence at ESC with additional data submissions completed for AHA

Significant Market Opportunity

4M deaths per year in Europe
WHO region due to CVD¹

~€210B

annual CVD costs to European Union²

10+ years of market
exclusivity in Europe

1. ESC: Cardiovascular Disease Statistics 2019.
2. European Heart Network. European Cardiovascular Disease Statistics 2017. <https://ehnhheart.org/cvd-statistics/cvd-statistics-2017.html>. Accessed January 2022




Europe To Date in 2022:

- ✓ Successfully concluded reimbursement and negotiations in **Sweden, England, Wales** and **Northern Ireland** and individual reimbursement achieved in **Denmark**.
 - Positive NICE (UK) and TLV (SE) assessments at premium prices vs. major CV medicines England & Wales: \$1,987/year* ; Sweden: \$1,827/year*
 - England & Wales formulary inclusions progressing rapidly
 - Sweden commercially launched and UK ramping up for October 2022 commercial sales
- ✓ Progress on other reimbursement discussions in European markets
 - **France, Spain, Netherlands** and **Austria** completed recommendations for reimbursement – price negotiations in progress
 - **Italy, Norway** and **Finland** reimbursement process progressing to the next stages
 - **Germany**: Viable reimbursement could not be reached; Amarin ceased commercial activities in Germany effective 9/1; arbitration concludes November 2022
- ✓ Further market expansion in EU
 - **Portugal, Switzerland** and **Scotland** reimbursement dossiers submitted – reimbursement process ongoing
 - **Belgium** submission planned in October 2022

*Based on US dollar exchange rate on 9/9/2022

Progress on European Product Commercialization



*Secured individual reimbursement; full reimbursement submission in process | **Initial filing denied; refiling reimbursement submission | ***Reimbursement arbitration discussions ongoing | ****Scientific Evidence Assessment/Recommendation ongoing; Reimbursement Price Negotiations initiated in parallel

International Growth Expansion Through Partnerships Represents Potential \$1B Opportunity

Plans to Bring Unique Cardioprotective Benefits of VASCEPA/VAZKEPA to 20 Additional Markets

1ST WAVE 2022
UP TO

6

COUNTRIES

2ND WAVE 2023
UP TO

9

COUNTRIES

3RD WAVE 2024
UP TO

5

COUNTRIES

Supported by REDUCE-IT Study and U.S. FDA and EMA Filings

REDUCE-IT Sub-Population Data Featured at ESC 2022

LATE-BREAKING SCIENCE PRESENTATION

Session: Latest science in primary and secondary prevention and environmental health

“SIGNIFICANT REDUCTION IN ST-ELEVATION MI WITH ICOSAPENT ETHYL IN REDUCE-IT”

Deepak L. Bhatt, Robert P. Giugliano, Ph. Gabriel Steg, Michael Miller, et al.

Pre-Specified, Post-Hoc Analyses Showed VASCEPA/VAZKEPA Significantly Reduced STEMI by 40% and NSTEMI by 27%

ORAL PRESENTATION

Session: Optimal risk factor therapy in high-risk patients

“ICOSAPENT ETHYL DIMINISHES CVD RISK IN SMOKERS: REDUCE-IT SMOKING”

Michael Miller, Deepak L. Bhatt, Ph. Gabriel Steg, Eliot A. Brinton, et al.

Post-Hoc Analysis Showed VASCEPA/VAZKEPA Significantly Reduced First and Total Cardiovascular Events in Combined Current and Former Smokers by 23% and 29% Respectively

Second Half 2022 Drivers of Success

- ❑ Maintaining stabilization of U.S. Business
- ❑ Reduce operational spending as outlined in cost savings plan
- ❑ Completion of additional cash preservation initiatives to continue to reduce cash burn
- ❑ Successful VAZKEPA Commercialization in the UK
- ❑ Potential pricing & reimbursement decisions in additional major EU markets (including Spain, France, Italy, Netherlands)
- ❑ Achieve international regulatory approvals in up to 6 countries and further partnership activities
- ❑ Continue to generate additional data evidence in support of VASCEPA/VAZKEPA globally
- ❑ Maintain active presence at medical meetings including upcoming AHA meeting in November

AMARIN

Vascepa[®]
(icosapent ethyl)

Vazkepa[®]
(icosapent ethyl)

THANK YOU

Investor Presentation

May 2022